YMI024 for Coronary Artery Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this Phase 2b study is to investigate the efficacy in reducing systemic inflammation, safety, tolerability, and dose response of five doses of YMI024, as compared to placebo in adult participants with stable coronary artery disease (CAD) and residual inflammatory risk defined by elevated high-sensitivity C-reactive protein (hsCRP) (≥2 mg/L)
Who Is on the Research Team?
Novartis Pharmaceuticals
Principal Investigator
Novartis Pharmaceuticals
Are You a Good Fit for This Trial?
This trial is for adults aged 18-80 with stable coronary artery disease, a history of heart attack or certain heart procedures at least 1-6 months ago, high inflammation levels (hsCRP ≥2 mg/L), and evidence of significant artery narrowing. People with moderate kidney disease can join if their kidney function meets specific criteria.Inclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- YMI024
Trial Overview
The study tests five different doses of an experimental drug called YMI024 versus a placebo to see how well it reduces inflammation in people with stable coronary artery disease. Participants are randomly assigned to receive either YMI024 or placebo.
How Is the Trial Designed?
6
Treatment groups
Experimental Treatment
Placebo Group
Participants receive YMI024 Dose 5 in addition to standard-of-care therapies.
Participants receive YMI024 Dose 4 in addition to standard-of-care therapies.
Participants receive YMI024 Dose 3 in addition to standard-of-care therapies.
Participants receive YMI024 Dose 2 in addition to standard-of-care therapies.
Participants receive YMI024 Dose 1 in addition to standard-of-care therapies.
Participants receive a matching placebo in addition to standard-of-care therapies
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.